Literature DB >> 20061791

Androgen receptor sequence and variations in several common prostate cancer cell lines.

Caitlin E Baum1, Sandra B Ockers, Bevin C English, Douglas K Price, Oliver Sartor, William D Figg.   

Abstract

The androgen receptor gene (AR) plays an important role in molecular signaling and regulation and the subsequent cellular growth of prostate cancer. In addition, it is a highly variable region of the genome. We used direct nucleotide sequencing to genotype the entire exogenous coding region of the androgen receptor in ten commonly used prostate cancer cell lines. Our analysis confirmed the presence or absence of several known SNPs in the cell lines studied. We also assayed the number of CAG-repeat and GGC-repeat sequences for each for the ten cell lines. Our analysis identified three new mutations, one each in the DU145, LnCAP and RWPE-2 cell lines. In DU145, the DNA isolated in our lab was heterozygous at G527G (T>C transition), a polymorphism not previously reported. The LnCAP cells cultured in our lab were found to have a T>C transition (heterozygous), resulting in a S641P change that was not present in the ATCC cell line DNA. Lastly, a homozygous G>T transversion was found in RWPE-2 cells, resulting in the S187I change. This is potentially significant for use in cell culture and future cell model development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061791      PMCID: PMC2874092          DOI: 10.4161/cbt.9.5.10891

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  13 in total

Review 1.  The androgen receptor: unlocking the secrets of its unique transactivation domain.

Authors:  Howard C Shen; Gerhard A Coetzee
Journal:  Vitam Horm       Date:  2005       Impact factor: 3.421

2.  A Stu I polymorphism in the human androgen receptor gene (AR).

Authors:  J Lu; M Danielsen
Journal:  Clin Genet       Date:  1996-06       Impact factor: 4.438

3.  Androgen receptor expression in androgen-independent prostate cancer cell lines.

Authors:  A Chlenski; K Nakashiro ; K V Ketels; G I Korovaitseva; R Oyasu
Journal:  Prostate       Date:  2001-04       Impact factor: 4.104

Review 4.  The androgen receptor gene and its influence on the development and progression of prostate cancer.

Authors:  J S Montgomery; D K Price; W D Figg
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

5.  Phenotypic and genotypic characterization of commonly used human prostatic cell lines.

Authors:  S Mitchell; P Abel; M Ware; G Stamp; E Lalani
Journal:  BJU Int       Date:  2000-05       Impact factor: 5.588

Review 6.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.

Authors:  J Veldscholte; C A Berrevoets; C Ris-Stalpers; G G Kuiper; G Jenster; J Trapman; A O Brinkmann; E Mulder
Journal:  J Steroid Biochem Mol Biol       Date:  1992-03       Impact factor: 4.292

7.  Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.

Authors:  X Y Zhao; B Boyle; A V Krishnan; N M Navone; D M Peehl; D Feldman
Journal:  J Urol       Date:  1999-12       Impact factor: 7.450

8.  Molecular characterization of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Marileila Varella-Garcia; Christopher Korch; Widya U Johannes; E Erin Smith; Heidi L Miller; Steven K Nordeen; Gary J Miller; M Scott Lucia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

9.  Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.

Authors:  L G Wang; L Ossowski; A C Ferrari
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

Review 10.  Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease.

Authors:  B P Brooks; K H Fischbeck
Journal:  Trends Neurosci       Date:  1995-10       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.